Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
51.1M
-
Number of holders
-
175
-
Total 13F shares, excl. options
-
35.6M
-
Shares change
-
+599K
-
Total reported value, excl. options
-
$808M
-
Value change
-
+$10.2M
-
Put/Call ratio
-
0.88
-
Number of buys
-
86
-
Number of sells
-
-80
-
Price
-
$22.68
Significant Holders of REGENXBIO Inc. - Common Stock, par value $0.0001 per share (RGNX) as of Q4 2022
207 filings reported holding RGNX - REGENXBIO Inc. - Common Stock, par value $0.0001 per share as of Q4 2022.
REGENXBIO Inc. - Common Stock, par value $0.0001 per share (RGNX) has 175 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 35.6M shares
of 51.1M outstanding shares and own 69.71% of the company stock.
Largest 10 shareholders include BlackRock Inc. (6.69M shares), VANGUARD GROUP INC (4.27M shares), JPMORGAN CHASE & CO (3.79M shares), STATE STREET CORP (2.72M shares), Redmile Group, LLC (1.91M shares), RTW INVESTMENTS, LP (1.85M shares), DIMENSIONAL FUND ADVISORS LP (1.36M shares), Aquilo Capital Management, LLC (898K shares), GEODE CAPITAL MANAGEMENT, LLC (733K shares), and BIOIMPACT CAPITAL LLC (621K shares).
This table shows the top 175 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.